設研院(300732.SZ):擬投資參與蘭考至原陽高速公路蘭考至封丘段特許經營項目
格隆匯 7 月 31日丨設研院(300732.SZ)公佈,公司第二屆董事會第二十二次會議決議,審議通過了《關於投資參與蘭考至原陽高速公路蘭考至封丘段特許經營項目的議案》;
為進一步實現資源的有效配置,促進產業鏈上下游的整合,發揮公司全過程技術管理優勢,推動公司積極參與項目資本運作,同意公司投資參與蘭考至原陽高速公路蘭考至封丘段特許經營項目。公司預計出資7000萬元左右,佔項目公司註冊資本的5%。公司參與該項目投資,既能獲得投資收益,又有利於公司全面承接項目的勘察設計、工程監理及檢測等業務。此次投資不構成關聯交易,不構成重大資產重組,不需要提交股東大會審議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.